☆ 4.6 Article

Anti-CD20 therapies decrease humoral immune response to SARS-CoV-2 in patients with multiple sclerosis or neuromyelitis optica spectrum disorders

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Infectious Diseases

Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study

Wan Ni Chia et al.

Summary: The study investigated the dynamics of neutralising antibody response in patients who have recovered from COVID-19, finding great variations and suggesting that predicting immune longevity can only be accurately determined at the individual level. The findings emphasize the importance of public health and social measures in the ongoing pandemic outbreak response, and may have implications for the longevity of immunity after vaccination.

LANCET MICROBE (2021)

添加到收藏夹

Article Clinical Neurology

Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis

Maria P. Sormani et al.

Summary: This study assessed the impact of immunosuppressive and immunomodulatory therapies on the severity of COVID-19 in people with multiple sclerosis. Therapy with an anti-CD20 agent and recent use of methylprednisolone were associated with increased risk of severe COVID-19.

ANNALS OF NEUROLOGY (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

Adaptive immunity to SARS-CoV-2 and COVID-19

Alessandro Sette et al.

Summary: The adaptive immune system, consisting of B cells, CD4(+) T cells, and CD8(+) T cells, plays varying roles in different viral infections and vaccines. Studies are showing that CD4(+) T cells, CD8(+) T cells, and neutralizing antibodies all play a part in controlling SARS-CoV-2 in COVID-19 cases, emphasizing the importance of understanding adaptive immunity in combating the disease.

CELL (2021)

添加到收藏夹

Review Biotechnology & Applied Microbiology

B cell depletion therapies in autoimmune disease: advances and mechanistic insights

Dennis S. W. Lee et al.

Summary: B cells have been found to actively participate in autoimmune diseases, leading to the clinical success of B cell depletion therapies like those targeting CD20, CD19, and BAFF. Despite limited impact on antibody levels and plasma cells in controlling the disease, research on B cells is constantly evolving and developing.

NATURE REVIEWS DRUG DISCOVERY (2021)

添加到收藏夹

Article Clinical Neurology

Untreated patients with multiple sclerosis: A study of French expert centers

Xavier Moisset et al.

Summary: Despite reimbursement for disease-modifying therapies (DMTs) for patients with multiple sclerosis (MS) in France, a significant proportion of patients remain untreated, especially those with progressive MS. The study found that main factors contributing to nontreatment included a lower number of lesions on brain MRI and a lower EDSS score.

EUROPEAN JOURNAL OF NEUROLOGY (2021)

添加到收藏夹

Letter Urology & Nephrology

Decline and loss of anti-SARS-CoV-2 antibodies in kidney transplant recipients in the 6 months following SARS-CoV-2 infection

Nathalie Chavarot et al.

KIDNEY INTERNATIONAL (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Rapid decline of neutralizing antibodies against SARS-CoV-2 among infected healthcare workers

Stephane Marot et al.

Summary: This study found that SARS-CoV-2 infection can induce neutralizing antibody response correlated with antibody levels, but this neutralizing activity declines after two months post-disease onset, suggesting the need for maintaining infection prevention measures and considering periodic vaccination boosts.

NATURE COMMUNICATIONS (2021)

添加到收藏夹

Article Infectious Diseases

Performance of 30 commercial SARS-CoV-2 serology assays in testing symptomatic COVID-19 patients

Christelle Vauloup-Fellous et al.

Summary: This study evaluated the clinical performances of 30 COVID-19 assays, with only 4 rapid tests and 3 automated/manual tests meeting specified criteria. Serology provides valuable information during the COVID-19 pandemic, but inconsistent performances were observed among the evaluated commercial assays.

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Medicine, General & Internal

Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study

Christian Holm Hansen et al.

Summary: The study investigated the protection against SARS-CoV-2 reinfection, with results showing an 80.5% protection rate for individuals previously infected. Even in the population aged 65 years and older, the protection rate against reinfection reached 47.1%, with no significant differences observed by gender or time since infection.

LANCET (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Influence of obesity on serum levels of SARS-CoV-2-specific antibodies in COVID-19 patients

Daniela Frasca et al.

Summary: This study investigated the impact of obesity on the immune response of COVID-19 patients, revealing a lower level of specific SARS-CoV-2 IgG antibodies in obese patients, which were negatively associated with Body Mass Index. The results indicated a negative correlation between antibody levels in obese patients and metabolic markers of inflammaging and pulmonary inflammation, while showing a positive association with nonesterified fatty acids.

PLOS ONE (2021)

添加到收藏夹

Article Clinical Neurology

Outcomes and Risk Factors Associated With SARS-CoV-2 Infection in a North American Registry of Patients With Multiple Sclerosis

Amber Salter et al.

Summary: This study examined outcomes and risk factors associated with COVID-19 clinical severity in a large, diverse cohort of North American patients with multiple sclerosis. The study found that ambulatory disability, older age, male sex, Black race, cardiovascular comorbidities, and recent corticosteroid use were associated with increased odds of worse clinical severity in MS patients with COVID-19. Knowledge of these risk factors may help improve the treatment and monitoring of these patients.

JAMA NEUROLOGY (2021)

添加到收藏夹

Article Clinical Neurology

Rituximab-Induced Hypogammaglobulinemia and Infections in AQP4 and MOG Antibody-Associated Diseases

Alexandre Avouac et al.

Summary: Rituximab used as maintenance therapy in CNS inflammatory diseases is frequently associated with reduced IgG levels and increases the infection risk of the most vulnerable patients.

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2021)

添加到收藏夹

Article Medicine, General & Internal

Association of Age With SARS-CoV-2 Antibody Response

He S. Yang et al.

Summary: The study found that there are distinct viral-specific antibody response profiles in different age groups with children showing higher levels of antibody response. Therefore, age-targeted strategies for disease screening, management, and vaccine development may be necessary.

JAMA NETWORK OPEN (2021)

添加到收藏夹

Article Clinical Neurology

Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies

Gustavo Luna et al.

JAMA NEUROLOGY (2020)

添加到收藏夹

Article Medicine, General & Internal

A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19

B. Cao et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Clinical Neurology

Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis

Celine Louapre et al.

JAMA NEUROLOGY (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19

Takuya Sekine et al.

CELL (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity

Carolyn Rydyznski Moderbacher et al.

CELL (2020)

添加到收藏夹

Article Clinical Neurology

Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis The VELOCE study

Amit Bar-Or et al.

NEUROLOGY (2020)

添加到收藏夹

Article Medicine, General & Internal

Ofatumumab versus Teriflunomide in Multiple Sclerosis

Stephen L. Hauser et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Infectious Diseases

Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison

Nicole Stoesser

LANCET INFECTIOUS DISEASES (2020)

添加到收藏夹

Letter Clinical Neurology

Beyond COVID-19: DO MS/NMO-SD patients treated with anti-CD20 therapies develop SARS-CoV2 antibodies?

Elisabeth Maillart et al.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)

添加到收藏夹

Article Clinical Neurology

Treatment of neuromyelitis optica with rituximab: a 2-year prospective multicenter study

Philippe Cabre et al.

JOURNAL OF NEUROLOGY (2018)

添加到收藏夹

Article Medicine, General & Internal

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis

S. L. Hauser et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

添加到收藏夹

Review Clinical Neurology

Disease-modifying therapies and infectious risks in multiple sclerosis

Alexander Winkelmann et al.

NATURE REVIEWS NEUROLOGY (2016)

添加到收藏夹

Article Clinical Neurology

A 5-Year Follow-up of Rituximab Treatment in Patients With Neuromyelitis Optica Spectrum Disorder

Su-Hyun Kim et al.

JAMA NEUROLOGY (2013)

添加到收藏夹

Article Rheumatology

Immunization Responses in Rheumatoid Arthritis Patients Treated With Rituximab Results From a Controlled Clinical Trial

Clifton O. Bingham et al.

ARTHRITIS AND RHEUMATISM (2010)

添加到收藏夹

Article Rheumatology

Humoral Responses After Influenza Vaccination Are Severely Reduced in Patients With Rheumatoid Arthritis Treated With Rituximab

Sander van Assen et al.

ARTHRITIS AND RHEUMATISM (2010)

添加到收藏夹

Article Clinical Neurology

Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial

Amit Bar-Or et al.

ANNALS OF NEUROLOGY (2008)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.